Literature DB >> 17289223

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.

P Oster1, J O'Hallahan, I Aaberge, S Tilman, E Ypma, D Martin.   

Abstract

To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of >1,000,000 people under 20 years. After the three-dose course 75% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17289223     DOI： 10.1016/j.vaccine.2007.01.023

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  23 in total

1.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008.

Authors:  Mignon du Plessis; Chivonne Moodley; Kedibone M Mothibeli; Azola Fali; Keith P Klugman; Anne von Gottberg
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

3.  Pathogenesis Mediated by Bacterial Membrane Vesicles.

Authors:  William J Gilmore; Natalie J Bitto; Maria Kaparakis-Liaskos
Journal:  Subcell Biochem       Date:  2021

Review 4.  Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control.

Authors:  Paul Balmer; Laura J York
Journal:  Ther Adv Vaccines Immunother       Date:  2018-06-21

5.  A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.

Authors:  Wildaliz Nieves; Hailey Petersen; Barbara M Judy; Carla A Blumentritt; Kasi Russell-Lodrigue; Chad J Roy; Alfredo G Torres; Lisa A Morici
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

6.  A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.

Authors:  Wildaliz Nieves; Saja Asakrah; Omar Qazi; Katherine A Brown; Jonathan Kurtz; David P Aucoin; James B McLachlan; Chad J Roy; Lisa A Morici
Journal:  Vaccine       Date:  2011-08-24       Impact factor: 3.641

7.  Biogenesis of outer membrane vesicles in Serratia marcescens is thermoregulated and can be induced by activation of the Rcs phosphorelay system.

Authors:  Kenneth J McMahon; Maria E Castelli; Eleonora García Vescovi; Mario F Feldman
Journal:  J Bacteriol       Date:  2012-04-06       Impact factor: 3.490

8.  Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen.

Authors:  David M Vu; Tracy T Wong; Dan M Granoff
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

9.  Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.

Authors:  Caroline Trotter; Jamie Findlow; Paul Balmer; Ann Holland; Rita Barchha; Nick Hamer; Nick Andrews; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

10.  Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Authors:  Synne Sandbu; Berit Feiring; Philipp Oster; Oddveig S Helland; Hilde S W Bakke; Lisbeth M Naess; Audun Aase; Ingeborg S Aaberge; Anne-Cathrine Kristoffersen; Kjersti M Rydland; Sandrine Tilman; Hanne Nøkleby; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.